Global Eylea Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

Overview and Scope

Eylea is a type of drug injected into the eye that helps slow vision loss and certain other diseases by blocking the leaking and growth of fluid from abnormal blood vessels from the back of the eye. It is used to treat age-related macular degeneration (AMD).

Sizing and Forecast

The eylea market size has grown strongly in recent years. It will grow from $7.8 billion in 2023 to $8.19 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to diabetic macular edema (dme) prevalence, clinical efficacy and safety profile, competition with other anti-vegf therapies, approval for various retinal conditions, shift towards intravitreal injections..

The eylea market size is expected to see strong growth in the next few years. It will grow to $10.16 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to emerging therapeutic indications, introduction of biosimilar competition, increasing awareness and diagnosis, real-world evidence and post-market studies, patient preference for less frequent injections.. Major trends in the forecast period include advancements in imaging technologies, telemedicine and remote monitoring, patient assistance programs, advances in drug delivery technologies, retinal imaging technologies, clinical trials for new indications..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Segmentation & Regional Insights

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications

North America was the largest region in the eylea market in 2023. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of ocular diseases is expected to propel the Eylea market. Ocular diseases refer to an eye condition that interferes with the ability of the eye properly function and negatively affects the vision and clarity of the eye. They often don’t have any symptoms until they have become very advanced. Eylea treats conditions such as ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, which damages the retina or macula that affects the vision. Eylea blocks the protein that develops new weaker blood vessels and slows down the retina’s swelling caused by a blockage in the blood vessels. For instance, in October 2022, according to the BrightFocus Foundation, a US-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, there were currently 80 million individuals with glaucoma across the globe, with a projected increase to more than 111 million by the year 2040. Therefore, the increasing prevalence of ocular diseases is driving the Eylea market.

Key Industry Players

Major companies operating in the eylea market are focused on developing biologic medications such as aflibercept biosimilar to gain a competitive advantage. An Aflibercept Biosimilar is a biologically similar version of the reference drug aflibercept, designed to have no clinically meaningful differences and offering a cost-effective alternative for the treatment of specific eye conditions. For instance, in September 2023, Biocon Biologics Ltd., a India based biopharmaceutical company, received marketing authorization from the European Commission (EC) for YESAFILI, a biosimilar of Aflibercept, in the European Union (EU). This approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July. YESAFILI is an ophthalmology product designed for the treatment of various eye conditions, and its approval signifies its comparability in terms of quality, safety, and efficacy to the reference product Eylea (aflibercept).

The eylea market report table of contents includes:

1. Executive Summary

2. Eylea Market Characteristics

3. Eylea Market Trends And Strategies

4. Eylea Market – Macro Economic Scenario

5. Global Eylea Market Size and Growth

31. Global Eylea Market Competitive Benchmarking

32. Global Eylea Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Eylea Market

34. Eylea Market Future Outlook and Potential Analysis

35. Appendix

Explore the trending research reports from TBRC: